CAS: 40782-54-5; 4-(Heptyloxy)Benzoyl Chloride

上下游产品

CAS号15872-42-1 4-正庚氧基苯甲酸 | CAS号629-04-9 1-溴庚烷 | CAS号79-37-8 草酰氯 | CAS号99-96-7 4-羟基苯甲酸 | CAS号154845-73-5 ethyl 4-heptoxy... | CAS号120-47-8 尼泊金乙酯 | CAS号111-70-6 正庚醇 | CAS号16782-08-4 四羟基苯甲酸一钾 | CAS号4282-40-0 1-碘庚烷 | CAS号99-76-3 尼泊金甲酯 | CAS号33905-65-6 (4-hydroxypheny... | CAS号61519-00-4 4-(Heptyloxy)th... | CAS号61519-01-5 S-(4-pentoxyphe...

📜4-正庚氧基苯甲酸置于氯化亚砜体系中,用 苯 作为反应溶剂,化学反应生成 4-庚氧基苯甲酰氯
参考文献:带有末端金属的卡拉米奇有机金属液晶.β-二酮二羰基铑(i)配合物的合成及液晶性质
标题:带有末端金属的卡拉米奇有机金属液晶.β-二酮二羰基铑(i)配合物的合成及液晶性质
摘要:通过配体与[rh(co)2(μ-Cl)] 2的反应,制备了一系列新型的基于γ-取代的β-二酮配体与末端金属rh(i)的有机金属配合物.配体和配合物的同构已使用dsc和偏光显微镜进行了研究.发现n=7,8,9,10,11的非介晶配体可以通过与金属直接配位而形成液晶相.还讨论了末端碳原子数对同晶型的影响.
DOI:10.1016/s0022-328X(97)00653-0

专利信息

专利号:UA-5633-U
优先权日:2004-07-23
标 题:4 (4-H-ALCOXYBENZOYLOXY) -3-BROMOBENZOIC ACIDS AS INTERMEDIATES FOR THE SYNTHESIS OF LIQUID CRYSTAL MATERIALS

专利号:US-8816121-B2
优先权日:2010-06-09
标 题:GLP-1 receptor stabilizers and modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; HUANG LIMING; TAMIYA JUNKO; GRIFFITH MARK T; FOWLER THOMAS; NOVAK ANDREW; KNAGGS MICHAEL; MEGHANI PREMJI
权利人:RECEPTOS INC
摘要:Compounds that bind the glucagon-like peptide 1 receptor (GLP-1) receptor are provided including compounds which are modulators of the GLP-1 receptors and compounds which are capable of inducing a stabilizing effect on the receptor for use in structural analysis of the GLP-1 receptor. Methods of synthesis, methods of therapeutic and/or prophylactic use, and methods of use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor of such compounds are provided.

专利号:US-9700543-B2
优先权日:2011-05-31
标题 :GLP-1 receptor stabilizers and modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; BRAHMACHARY ENUGURTHI; YEAGER ADAM RICHARD
权利人:CELGENE INT II SÀRL
摘要:Compounds that bind the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, methods of their therapeutic and/or prophylactic use, and methods of their use in stabilizing GLP-1 receptor in vitro for crystallization of the GLP-1 receptor are provided. Certain compounds may have activity as modulators or potentiators with respect to glucagon receptor, GIP receptor, GLP-1 and GLP-2 receptors, and PTH receptor on their own or in the presence of receptor ligands such as GIP(1-42), PTH(1-34), Glucagon(1-29), GLP-2(1-33), GLP-1(7-36), GLP-1(9-36), oxyntomodulin and exendin variants.